4-氯-3-(2-氯乙基)-2,8-二甲基喹啉 | 107622-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-3-(2-氯乙基)-2,8-二甲基喹啉
• 英文名称: 4-chloro-3-(2-chloro-ethyl)-2,8-dimethyl-quinoline
• 英文别名: 4-Chlor-3-(2-chlor-aethyl)-2,8-dimethyl-chinolin；2,8-Dimethyl-3-(2-chloroethyl)-4-chloroquinoline；4-chloro-3-(2-chloroethyl)-2,8-dimethylquinoline
• CAS: 107622-79-7
• 化学式: C₁₃H₁₃Cl₂N
• 分子量: 254.159
• InChiKey: HREKRRSBKFRWTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-氯-3-(2-氯乙基)-2,8-二甲基喹啉 在 disodium telluride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以48%的产率得到4,6-Dimethyl-2,3-dihydro-tellurolo[3,2-c]quinoline
  参考文献：
  名称：

  Raja, T K; Muthuvijayan, G; Reddy, P A, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1992, vol. 31, # 4, p. 270 - 272

  摘要：

  DOI：
• 作为产物：
  描述：

  邻甲苯胺 在 对甲苯磺酸 、 三氯氧磷 作用下， 生成 4-氯-3-(2-氯乙基)-2,8-二甲基喹啉
  参考文献：
  名称：

  二氢吡喃并[3,4-b]吡啶支架方便合成杂环化合物

  摘要：

  摘要图形抽象

  DOI：

  10.1080/00397911.2011.616274

文献信息

• Dihydropyrrolo quinoline derivatives
  申请人：SmithKline Beckman Intercredit B.V.

  公开号：US05051508A1

  公开（公告）日：1991-09-24

  1,4-Substituted 2,3-dihydropyrrolo[3,2-c]quinolines which are inhibitors of H.sup.+ K.sup.+ ATPase activity and useful as inhibitors of gastric acid secretion. A compound of the invention is 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline.

  1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂，可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。
• TOPICAL FORMULATIONS
  申请人：BECK Petra Helga

  公开号：US20100093691A1

  公开（公告）日：2010-04-15

  There is provided topical pharmaceutical compositions comprising compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description. These compositions can be used to treat microbial infections and to kill clinically latent microorganisms.

  提供了一种含有I式化合物的局部制药组合物，其中R1、R2、R3和X的含义在说明中给出。这些组合物可用于治疗微生物感染并杀死临床潜伏微生物。
• USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS
  申请人：Beck Petra Helga

  公开号：US20120231995A1

  公开（公告）日：2012-09-13

  There is provided the use of compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

  提供了使用式子I中的化合物，其中R1、R2、R3和X的含义在说明中给出，用于制备杀死临床潜伏微生物的药物。还提供了使用式子I中的化合物治疗微生物感染的方法，以及某些式子I中的化合物本身。
• Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SMITHKLINE BEECHAM INTERCREDIT B.V.

  公开号：EP0307078A1

  公开（公告）日：1989-03-15

  in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂)nOH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

  C₁₋₄烷硫基、C₁₋₄烷酰基、氨基、R⁵至 R⁹相同或不同且各自为氢、C₁₋₆alkyl、C₁₋₆alkoxy、C₁₋₆烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C₁₋₆烷酰基、三氟甲基或硝基，R¹⁰除其他外为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、羟基、-CH₂OH、C₁₋₆烷硫基、NH(CH₂)nOH（其中 n 为 0 至 4）或氨基；和 A 是-(CH₂)₂-、(CH₂)₃- 或-CH=CH-；它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
• Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogs of 4-(arylamino)quinolines
  作者：Thomas H. Brown、Robert J. Ife、David J. Keeling、Shiona M. Laing、Colin A. Leach、Michael E. Parsons、Carolyn A. Price、David R. Reavill、Kenneth J. Wiggall

  DOI：10.1021/jm00164a010

  日期：1990.2

  The 4-(arylamino)quinoline 4, previously described as an antiulcer compound, is shown to be an inhibitor of the gastric (H+/K+)-ATPase. It is postulated that 1-arylpyrrolo[3,2-c]quinolines 6 act as conformationally restrained analogues of 4. A series of derivatives of 6 has been prepared and shown to be potent inhibitors of the target enzyme in vitro. Substitution in the ortho position of the aryl ring is important for activity. Unsaturation in the 5-membered ring makes little difference, but introduction of heteroatoms into the same ring markedly reduces activity. In more detailed kinetic experiments, 15c and 4 both show reversible, K(+)-competitive binding to the enzyme, with submicromolar Ki values. The compounds appear to act at the lumenal face of the enzyme and to require protonation for activity. Several compounds in the series are shown to be potent inhibitors of pentagastrin-stimulated acid secretion in the rat.